Transition Corporate Finance

Amsterdam (December 2025) – Confocal NL (“Confocal”), an innovative technology company that develops and produces advanced live cell imaging systems that preserve cell integrity while delivering superior speed, resolution, and depth, has secured additional series A financing. This investment supports the further scaling of the company’s operational organization and enables Confocal to accelerate its international growth strategy. The financial details of the transaction have not been disclosed.

Willem op de Hoek, partner at TCF: “With Confocal’s cutting-edge live call imaging microscopy systems, the drug discovery cycle can be shortened by 2–3 years. We are proud to contribute to the further roll-out of this impressive technology through the provision of growth financing. ’Big thank you’ to the management and shareholders for the pleasant collaboration.”

Transition Corporate Finance (TCF) acted as advisor to the Undisclosed Investor on this financing.